Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Lexaria Announces Positive Feedback from Pre-IND Meeting
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
Kelowna, British Columbia – TheNewswire - June 21, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce the signing of two agreements with Atlanta-based BevNology LLC (“BevNology”).